Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Gains from Investment Securities (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Gains from Investment Securities for 10 consecutive years, with -$780000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities rose 35.11% to -$780000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.0 million, a 0.0% change, with the full-year FY2025 number at $2.0 million, changed 0.0% from a year prior.
  • Gains from Investment Securities was -$780000.0 for Q4 2025 at Ultragenyx Pharmaceutical, down from $360000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $4.0 million in Q1 2023 to a low of -$6.0 million in Q2 2023.
  • A 5-year average of $139300.0 and a median of $231000.0 in 2023 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: plummeted 1278.43% in 2024, then surged 3900.0% in 2025.
  • Ultragenyx Pharmaceutical's Gains from Investment Securities stood at $455000.0 in 2021, then soared by 32.75% to $604000.0 in 2022, then plummeted by 83.11% to $102000.0 in 2023, then tumbled by 1278.43% to -$1.2 million in 2024, then surged by 35.11% to -$780000.0 in 2025.
  • Per Business Quant, the three most recent readings for RARE's Gains from Investment Securities are -$780000.0 (Q4 2025), $360000.0 (Q3 2025), and $1.6 million (Q2 2025).